About this trial
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.
Eligibility criteria
Qualifiers
Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.
Male and female patients older than 21 years.
Willingness to participate and ability to provide informed consent.
Disqualifiers
implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)
iron-based tattoos
any other pieces of metal or devices that are not MR-Safe anywhere in the body
patients who exhibit noticeable anxiety and/or claustrophobia into the MRI scanner
Trial design
Treatments tested in this trial
- 23NaMRI Scan
- Potassium Chloride (KCl)
Treatment groups
Sponsors and collaborators
Jens Titze
Lead sponsor
Duke-NUS Graduate Medical School
Sponsor institution
Changi General Hospital
Collaborator
Singapore General Hospital
Collaborator
Sengkang General Hospital
Collaborator